Zurich Cantonal Bank
TBPH icon

Zurich Cantonal Bank’s Theravance Biopharma TBPH Stock Holding History

Zurich Cantonal Bank’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-868
Closed -$16.2K – 3398
2025
Q4 		$16.2K Buy
+868
New +$14.4K ﹤0.01% 2472

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zurich Cantonal Bank's TBPH Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in Theravance Biopharma (TBPH) in Q1 2026: 15,309 shares worth $248K. The stake represents ﹤0.01% of the portfolio and ranks #2173 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in TBPH as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in TBPH in Q2 2014 and has held it in 40 quarters since. The position peaked at $364K in Q2 2014. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Zurich Cantonal Bank held 15,309 shares of Theravance Biopharma worth $248K as of Q1 2026.
  • Theravance Biopharma was a new Zurich Cantonal Bank position in Q1 2026.
  • Theravance Biopharma made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #2173 holding.
  • Zurich Cantonal Bank first reported a position in Theravance Biopharma in Q2 2014 and has held it in 40 quarters since.
  • Zurich Cantonal Bank's Theravance Biopharma position peaked at $364K in Q2 2014.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.